Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome

This second edition will feature updates for all chapters, including references as needed and, most importantly, the latest outcomes data for lipids, hypertension and overall risk reduction. It will also include a new chapter on incretins, amylin analogues and DPP-IV inhibitors as well as an expanded section on lipid disorders in the diabetic patient. New information on the role of the incretin system in the pathophysiology of the disease will also be detailed. Existing chapters will be edited for better brevity to accommodate the new chapters being added and to contain the length of the book to approximately 250 to 300 pages. Although it will not include CME certification, the feature of several multiple choice questions will be retained at the end of each chapter to add value.